Article Summary
May 26, 2020
A Score-Based Risk Model for Predicting Severe COVID-19 Infection as a Key Component of Lockdown Exit Strategy
[pre-print, not peer reviewed] Dagan et al. used retrospective data from all COVID-19 patients diagnosed by April 1, 2020 in a large healthcare organization (n=2,421) to develop a tool that sums over 10 risk factors to predict risk of severe COVID-19 illness or death (basic risk, high risk, very high risk). The risk score had similar sensitivity to detect severe cases of COVID-19 disease…
Visualizing the Invisible: The Effect of Asymptomatic Transmission on the Outbreak Dynamics of COVID-19
[pre-print, not peer reviewed] Peirlinck et al. used reported symptomatic case data, antibody seroprevalence studies, a mathematical epidemiology model, and a Bayesian framework to infer the epidemiological characteristics of COVID-19 and predict Rt. This approach found outbreak dynamics to be sensitive to Rt, the ratio of symptomatic to asymptomatic populations, and the infectious periods of both groups. For…
Risk Stratification of Hospitalized COVID-19 Patients through Comparative Studies of Laboratory Results with Influenza
[pre-print, not peer reviewed] Comparing clinical and laboratory results from 719 influenza and 973 COVID-19 patients from January to April, using parameters that are most significantly different between COVID-19 and influenza, COVID-19 patients were sub-classified into 5 clusters through a hierarchical clustering analysis. Risk stratification of these clusters using medical record review found that the highest-risk cluster had…
Coronavirus Disease 2019 Test Results After Clinical Recovery and Hospital Discharge Among Patients in China
PCR tests on nasopharyngeal and anal swabs from 60 patients who had been hospitalized for COVID-19 found evidence of persistent viral shedding following discharge. Samples were collected 4-24 days after index hospital discharge and 10 out of 60 patients had positive results (16.7%; 5 nasopharyngeal and 6 anal). None of these patients had clinical symptoms of COVID-19 at the time of sample collection except for occasional…
Analysis of Maternal Coronavirus Infections and Neonates Born to Mothers with 2019-NCoV; a Systematic Review
A systematic literature review that included 9 studies corresponding to 89 pregnant women with SARS-CoV-2 infection and their neonates found low-grade fever and cough were the predominant symptoms, and that fetal distress, premature rupture of membranes, and preterm labor were the most common prenatal complications. Two women required ICU admission and ventilation, and one developed multi-organ dysfunction. No maternal deaths…
Clinical Features and Outcomes of 105 Hospitalized Patients with COVID-19 in Seattle, Washington
A descriptive study of all laboratory-confirmed COVID-19 adult patients admitted to an academic medical center in Seattle, WA between March 2 and March 26, 2020 (n=105) found that 35% were admitted from a senior home or skilled nursing facility. Median age was 69 years and half were women. Three or more comorbidities were present in 55% of…
Incidence, Clinical Outcomes, and Transmission Dynamics of Severe Coronavirus Disease 2019 in California and Washington: Prospective Cohort Study.
Out of over 9 million healthcare plan enrollees in northern California, southern California, and Washington State, the cumulative incidence of first hospital admission for COVID-19 by April 22 was 15.6 per 100,000 persons in northern California, 23.3 per 100,000 persons in southern California, and 14.7 per 100,000 persons in Washington. Median duration of hospital stay was…
Safety, Tolerability, and Immunogenicity of a Recombinant Adenovirus Type-5 Vectored COVID-19 Vaccine: A Dose-Escalation, Open-Label, Non-Randomised, First-in-Human Trial
A phase 1 trial of an adenovirus type-5 vectored COVID-19 vaccine expressing the spike glycoprotein of SARS-CoV-2 was conducted in Wuhan, China (dose-escalation, single-center, open-label, non-randomized). Thirty-six participants received each dose of the vaccine (low, middle, high). At least one adverse reaction within 7 days of vaccination was reported in 83% of participants in the…
Determinants of COVID-19 Vaccine Acceptance in the U.S.
[pre-print, not peer reviewed] Out of 672 US adults surveyed during an online platform in May 2020, 450 (67%) said they would accept a COVID-19 vaccine if recommended for them. A greater acceptance the vaccine was found among males (72% vs 63%), adults older than 55 (78% vs 56-64%), Asians (81% vs 40-74%), and college and/or…
Remdesivir for the Treatment of Covid-19 – Preliminary Report
A double-blind, randomized, placebo-controlled trial of IV remdesivir (200mg on day 1, then 100mg daily for up to 9 days) in adults hospitalized with COVID-19 with evidence of lower respiratory tract involvement (n=1,059) found that, compared to placebo, recovery was 32% faster in those who received remdesivir (95%CI 12% to 55%; median recovery time 11 vs 15 days). Though not statistically significant, Remdesivir treatment was associated with…
Previous page Next page